Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188

1.

Botulinum toxin outcomes for idiopathic overactive bladder stratified by indication: lack of anticholinergic efficacy versus intolerability.

Makovey I, Davis T, Guralnick ML, O'Connor RC.

Neurourol Urodyn. 2011 Nov;30(8):1538-40. doi: 10.1002/nau.21150. Epub 2011 Aug 8.

PMID:
21826718
3.

Botulinum toxin injections for adults with overactive bladder syndrome.

Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD005493. doi: 10.1002/14651858.CD005493.pub3. Review.

PMID:
22161392
4.

Role of botulinum toxin-A in refractory idiopathic overactive bladder patients without detrusor overactivity.

Kanagarajah P, Ayyathurai R, Caruso DJ, Gomez C, Gousse AE.

Int Urol Nephrol. 2012 Feb;44(1):91-7. doi: 10.1007/s11255-011-9979-9. Epub 2011 Jun 4.

PMID:
21643644
5.

Sacral neuromodulation and intravesical botulinum toxin for refractory overactive bladder.

Kantartzis K, Shepherd J.

Curr Opin Obstet Gynecol. 2012 Oct;24(5):331-6. doi: 10.1097/GCO.0b013e3283573ff9. Review.

PMID:
22922403
6.

Botulinum toxin A submucosal injection for refractory non-neurogenic overactive bladder: early outcomes.

Okamura K, Nojiri Y, Ameda K, Namima T, Suzuki M, Inoue K, Ogawa T, Gotoh M, Homma Y.

Int J Urol. 2011 Jun;18(6):483-7. doi: 10.1111/j.1442-2042.2011.02768.x. Epub 2011 Apr 13.

7.

[Prospective study of the clinical and urodynamic results of intradetrusor botulinum toxin injections for the treatment of neurogenic overactive bladder].

Bentaleb Y, Castel-Lacanal E, Sallusto F, De Boissezon X, Malavaud B, Marque P, Rischmann P, Gamé X.

Prog Urol. 2008 Jul;18(7):449-55. doi: 10.1016/j.purol.2008.03.014. Epub 2008 May 27. French.

PMID:
18602606
8.

Intravesical botulinum type A toxin injection in patients with overactive bladder: Trigone versus trigone-sparing injection.

Lucioni A, Rapp DE, Gong EM, Fedunok P, Bales GT.

Can J Urol. 2006 Oct;13(5):3291-5.

PMID:
17076955
9.

Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial.

Sahai A, Dowson C, Khan MS, Dasgupta P.

BJU Int. 2009 Jun;103(11):1509-15. doi: 10.1111/j.1464-410X.2009.08402.x. Epub 2009 Apr 15.

10.

Injections of Botulinum Toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury.

Chen G, Liao L.

Int Urol Nephrol. 2011 Sep;43(3):655-62. doi: 10.1007/s11255-010-9873-x. Epub 2010 Nov 26.

PMID:
21110094
11.

Antibodies after botulinum toxin A injection into musculus detrusor vesicae: incidence and clinical relevance.

Hegele A, Frohme C, Varga Z, Olbert P, Kranz J, Hofmann R.

Urol Int. 2011;87(4):439-44. doi: 10.1159/000332194. Epub 2011 Oct 18.

PMID:
22004911
12.
13.

Patient-reported side effects of intradetrusor botulinum toxin type a for idiopathic overactive bladder syndrome.

Bauer RM, Gratzke C, Roosen A, Hocaoglu Y, Mayer ME, Buchner A, Stief CG, May F.

Urol Int. 2011;86(1):68-72. doi: 10.1159/000316080. Epub 2010 Jul 15.

PMID:
20639617
14.

Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity.

Sahai A, Dowson C, Khan MS, Dasgupta P; GKT Botulinum Study Group..

Urology. 2010 Mar;75(3):552-8. doi: 10.1016/j.urology.2009.05.097. Epub 2009 Dec 29.

PMID:
20035984
15.

Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.

Schmid DM, Sauermann P, Werner M, Schuessler B, Blick N, Muentener M, Strebel RT, Perucchini D, Scheiner D, Schaer G, John H, Reitz A, Hauri D, Schurch B.

J Urol. 2006 Jul;176(1):177-85.

PMID:
16753396
16.

Effectiveness of botulinum-A toxin for the treatment of refractory overactive bladder in children.

Marte A, Borrelli M, Sabatino MD, Balzo BD, Prezioso M, Pintozzi L, Nino F, Parmeggiani P.

Eur J Pediatr Surg. 2010 May;20(3):153-7. doi: 10.1055/s-0029-1246193. Epub 2010 Jan 28.

PMID:
20112186
17.
18.
19.
20.

Supplemental Content

Support Center